Perrigo Company plc (NYSE:PRGO – Get Free Report) saw unusually large options trading on Friday. Stock investors purchased 11,734 call options on the company. This represents an increase of approximately 637% compared to the average volume of 1,593 call options.
Wall Street Analyst Weigh In
PRGO has been the topic of a number of recent research reports. Piper Sandler cut Perrigo from an “overweight” rating to a “neutral” rating and reduced their price objective for the company from $34.00 to $27.00 in a research note on Monday, January 6th. StockNews.com cut Perrigo from a “buy” rating to a “hold” rating in a research note on Wednesday, February 19th. Finally, Argus cut Perrigo from a “buy” rating to a “hold” rating in a research note on Tuesday, January 14th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $35.00.
Read Our Latest Analysis on PRGO
Insider Buying and Selling
Institutional Trading of Perrigo
Institutional investors and hedge funds have recently bought and sold shares of the stock. Franklin Resources Inc. purchased a new stake in Perrigo in the third quarter worth about $3,717,000. Foundry Partners LLC purchased a new position in shares of Perrigo during the third quarter valued at approximately $7,111,000. Barclays PLC lifted its holdings in shares of Perrigo by 44.8% during the third quarter. Barclays PLC now owns 120,502 shares of the company’s stock valued at $3,160,000 after purchasing an additional 37,268 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Perrigo by 65.1% during the third quarter. JPMorgan Chase & Co. now owns 541,000 shares of the company’s stock valued at $14,190,000 after purchasing an additional 213,221 shares during the last quarter. Finally, Citigroup Inc. lifted its holdings in shares of Perrigo by 94.1% during the third quarter. Citigroup Inc. now owns 151,520 shares of the company’s stock valued at $3,974,000 after purchasing an additional 73,457 shares during the last quarter. 95.91% of the stock is currently owned by hedge funds and other institutional investors.
Perrigo Trading Up 19.7 %
Shares of NYSE PRGO traded up $4.75 during trading hours on Friday, hitting $28.88. The company’s stock had a trading volume of 5,484,657 shares, compared to its average volume of 1,486,439. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.77 and a current ratio of 2.56. The stock has a market cap of $3.94 billion, a price-to-earnings ratio of -24.69 and a beta of 0.54. Perrigo has a 12 month low of $23.14 and a 12 month high of $33.46. The business has a 50-day simple moving average of $24.87 and a 200-day simple moving average of $26.18.
Perrigo (NYSE:PRGO – Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported $0.93 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.01. Perrigo had a positive return on equity of 7.38% and a negative net margin of 3.64%. The company had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.20 billion. On average, analysts anticipate that Perrigo will post 2.56 earnings per share for the current fiscal year.
Perrigo Increases Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 25th. Shareholders of record on Friday, March 7th will be issued a $0.29 dividend. The ex-dividend date is Friday, March 7th. This is a positive change from Perrigo’s previous quarterly dividend of $0.28. This represents a $1.16 annualized dividend and a yield of 4.02%. Perrigo’s dividend payout ratio (DPR) is -99.15%.
About Perrigo
Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.
Featured Stories
- Five stocks we like better than Perrigo
- The Role Economic Reports Play in a Successful Investment Strategy
- Analysts Lift Archer Aviation Stock Despite Earnings Miss
- Insider Trading – What You Need to Know
- 5 Best Gold ETFs for March to Curb Recession Fears
- How to Invest in Insurance Companies: A Guide
- 3 Stocks for Your Watchlist: Unlocking Tomorrow’s Winners Today
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.